# OnCo record idea-molecular-class-adjuvant-endometrial (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-molecular-class-adjuvant-endometrial/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-molecular-class-adjuvant-endometrial" ;
  schema:name "Molecular-class-directed adjuvant therapy in endometrial cancer"@en ;
  schema:description "Give adjuvant treatment by the tumour's molecular class rather than by stage and grade: nothing for POLE-mutated, immunotherapy for MMRd, chemotherapy plus targeted agents for p53-abnormal, hormones for NSMP."@en ;
  schema:url <https://onco.cc/ideas/idea-molecular-class-adjuvant-endometrial/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00411138> ;
  onco:cancers <https://onco.cc/cancers/endometrial/> ;
  onco:targets <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/megestrol-progestins/> ;
  onco:terms <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/terms/msi/> ;
  onco:trials <https://onco.cc/trials/portec-3/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-duo-e-jco-2023/>, <https://onco.cc/key-papers/paper-durvalumab-endometrial-j-immunother-cancer-2021/>, <https://onco.cc/key-papers/paper-durvalumab-endometrial-gynecol-oncol-2022/> .